|1.||Shannon, Harlan E: 2 articles (05/2005 - 01/2005)|
|2.||Barton, Matthew E: 1 article (05/2005)|
|3.||Bertorelli, Rosalia: 1 article (04/2005)|
|4.||Parker, Eric M: 1 article (04/2005)|
|5.||Reggiani, Angelo: 1 article (04/2005)|
|6.||Guthrie, Donald H: 1 article (04/2005)|
|7.||Fredduzzi, Silva: 1 article (04/2005)|
|8.||Forlani, Angelo: 1 article (04/2005)|
|9.||Varty, Geoffrey B: 1 article (04/2005)|
|10.||Hunter, John C: 1 article (04/2005)|
04/01/2005 - "LY456236 reduced operant responding at 30 mg/kg. Both mGluR5 and mGluR1 antagonists are effective in models of pain and anxiety. "
04/01/2005 - "The mGluR5 antagonists, 2-methyl-6-(phenylethynyl)pyridine (MPEP) and 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP), and the mGluR1 antagonist, (4-methoxy-phenyl)-(6-methoxy-quinazolin-4-yl)-amine HCl (LY456236), were tested in models of pain [mouse formalin test, rat spinal nerve ligation (SNL)] and anxiety [Vogel conflict, conditioned lick suppression (CLS)], and their efficacious effects were compared to any associated side effects. "
01/01/2005 - "In addition, LY456236 produced a dose-related increase in the stimulus intensity required to produce generalized seizures. "
01/01/2005 - "In amygdala-kindled male Sprague-Dawley rats, LY456236 produced dose-related decreases in behavioral and electrographic seizures at threshold stimulus intensity. "
01/01/2005 - "In male CF1 mice, LY456236 produced a dose-related inhibition of tonic extensor seizures in the threshold electroshock model, and limbic seizures in the 6-Hz focal seizure model. "
01/01/2005 - "In male and female DBA/2 mice, LY456236 produced a dose-related inhibition of sound-induced clonic-tonic seizures. "
05/01/2005 - "LY456236 blocked the seizures produced by 30 nmol but not by 400 nmol; dantrolene was ineffective in blocking seizures produced by either dose. "
|1.||metabotropic glutamate receptor type 1
|2.||metabotropic glutamate receptor 5
|3.||(4- methoxy- phenyl)- (6- methoxy- quinazolin- 4- yl)- amine HCl